Document is current
Any future updates will be listed below
-
Authors
Cavalieri, Stefano
De Cecco, Loris
Monzani, Dario
Mehanna, Hisham
Ferrarotto, Renata
Simon, Christian
Haddad, Robert
Saintigny, Pierre
Le Tourneau, Christophe
Licitra, Lisa
-
Funding
Funding for this research was provided by:
Ministero della Salute, Italy (Ricerca Corrente)
Fondazione Regionale per la Ricerca Biomedica (Supporting Personalized Treatment Decisions in Head and Neck Cancer through Big Data - SUPERTREAT)
ERAPerMed (Supporting Personalized Treatment Decisions in Head and Neck Cancer through Big Data - SUPERTREAT)
ERAPerMed (Supporting Personalized Treatment Decisions in Head and Neck Cancer through Big Data - SUPERTREAT)
- License Information
-
More Information
Article History
Received: 22 October 2025
Accepted: 2 March 2026
First Online: 14 March 2026
Competing interests
: Stefano Cavalieri (S.C.) declares occasional fees for participation as a speaker at conferences/congresses from AccMed; support for attending meetings and/or travel from AccMed, MultiMed Engineers srl, Care Insight sas, unrelated to the content of this work. Lisa Licitra (L.L.) declares the following conflicts of interest: research funds donated directly to the institute for clinical trials from AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La Roche Ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD, Novartis, Pfizer, Roche, and Buran; occasional fees for participation as a speaker at conferences/congresses or as a scientific consultant for advisory boards from AstraZeneca, Bayer, MSD, Merck-Serono, AccMed, Neutron Therapeutics, Inc., and Alentis. Pierre Saintigny declares the following conflicts of interest: research funds donated directly to the institute from Illumina, HTG Molecular Diagnostics, Roche, and BMS. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
